Although TrialSite reported yesterday that both the AstraZeneca and the Johnson & Johnson vaccine trials received the U.S. Food and Drug Administration (FDA) greenlight to resume, the AstraZeneca study had been in delay for several weeks in America. Recently, a University of Wisconsin-Madison principal investigator wanted it on the record that such pauses should be considered a good thing, not a negative. The fact that there is a pause in the study indicates that the FDA regulated system is healthy and functioning well, suggests the study’s principal investigator for UW-Madison, Dr. William Hartman.
Confidence at UW
After a nearly seven week pause, the AstraZeneca COVID-19 vaccine trial at UW, and other sites, is up and running again. Dr. Hartman shared that such pauses shouldn’t prompt worry but rather the opposite, greater confidence and trust in the process. Speaking to local Madison news, Dr. Hartman declared, “We have to realize that pauses like this are very common in trials.” He continued that, “The trials just aren’t under such media scrutiny.”
According to WKOW, prior to the study’s pause, up to 10,000 people were interested in participatin...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).